Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.

ABSTRACT: Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventio

SUBMITTER: Miyamoto K 

PROVIDER: S-EPMC7404220 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature